A feasibility study aims to predict SSRIs' response in major depression patients using blood-derived biomarkers

PI

• Revital Amiaz, MD (Psychiatry Department Sheba Medical Center)

‍DESCRIPTION

The study involves generating neuronal cells from MDD patients to further understand the biological underpinnings of the disorder and establish NeuroKaire's (formerly Genetika+) MDD disease model.

The study’s overarching aim is to investigate the potential of NeuroKaire's (formerly Genetika+) blood test to predict treatment outcomes in patients with clinical depression. The study explores the possibility of identifying subgroups of patients with similar biological profiles and utilizing NeuroKaire’s biological markers to monitor the effectiveness of treatment and predict relapse.‍

‍

PARTICIPANTS

60 subjects with MDD, 20 antidepressant treatment responsive, 20 antidepressant non-responders, and 20 antidepressant differential responders, enrolled in the study.